Table 2

Demographic, clinical, intervention-related and exercise-related characteristics of patients in the exercise and control group.

Exercise
(n=1944)
Control
(n=1571)
Demographic
Age, mean (SD) years54.9 (11.9)55.0 (11.6)
Age categories (years), n (%)
  < 50648 (33.3)501 (31.9)
  50–701070 (55.0)892 (56.8)
  ≥70216 (11.1)165 (10.5)
  Unknown10 (0.5)13 (0.8)
Sex, n (%)
  Men496 (25.5)396 (25.2)
  Women1448 (74.5)1175 (74.8)
Married/living with partner, n (%)
  Yes1150 (59.2)891 (56.7)
  No336 (17.3)294 (18.7)
  Unknown458 (23.6)386 (24.6)
Education level, n (%)
  Low/middle864 (44.4)657 (41.8)
  High816 (42.0)632 (40.2)
  Unknown264 (13.6)282 (18.0)
Clinical
BMI, mean (SD) kg/m2 27.08 (5.0)27.42 (5.3)
BMI categories, n (%)
  Underweight (BMI <18.5 kg/m2)13 (0.7)18 (1.2)
  Normal weight (BMI 18.5–<25 kg/m2)697 (35.9)513 (32.7)
  Overweight (BMI 25–<30 kg/m2)676 (34.8)549 (35.0)
  Obese (BMI ≥30 kg/m2)447 (23.0)390 (24.8)
  Unknown111 (5.7)101 (6.4)
Cancer type, n (%)
  Breast1297 (66.7)1056 (67.2)
  Male genitourinary287 (14.8)221 (14.1)
  Haematological190 (9.8)183 (11.7)
  Gastrointestinal126 (6.5)76 (4.8)
  Gynaecological16 (0.8)17 (1.1)
  Respiratory track23 (1.2)15 (1.0)
  Other5 (0.3)3 (0.2)
Surgery, n (%)*
  No265 (14.3)219 (14.8)
  Yes1458 (78.8)1144 (77.5)
  Unknown127 (6.9)113 (7.7)
Chemotherapy, n (%)
  No498 (25.6)412 (26.2)
  Prior to intervention663 (34.1)618 (39.3)
  During intervention715 (36.8)479 (30.5)
  Unknown68 (3.5)62 (4.0)
Radiotherapy, n (%)
  No850 (43.7)616 (39.2)
  Prior to intervention720 (37.0)650 (41.4)
  During intervention297 (15.3)253 (16.1)
  Unknown77 (4.0)52 (3.3)
Hormone therapy
  Breast cancer survivors (n= 2353), n (%)
   No672 (51.8)545 (51.6)
   Yes365 (28.1)261 (24.7)
   Unknown260 (20.1)250 (23.7)
  Prostate cancer survivors (n=508), n (%)
   No0 (0.0)0 (0.0)
   Prior to intervention50 (17.4)50 (22.6)
   During intervention190 (66.2)125 (56.6)
   Unknown47 (16.4)46 (20.8)
SCT, n (%)†
  Allogeneic40 (42.6)40 (42.1)
  Autologous54 (57.5)55 (57. 9)
Intervention related‡
Timing of intervention, n (%)
  Pre–during–following treatment40 (2.1)
  During treatment1113 (57.3)
  Following treatment791 (40.7)
Mode of intervention delivery, n (%)
  (Partly) Supervised1527 (78.6)
  Unsupervised417 (21.5)
Duration of intervention (weeks), n (%)
  ≤12644 (33.1)
  >12-24495 (25.5)
  >24605 (31.1)
  Unknown§200 (10.3)
Exercise related
Exercise frequency, n (%)
  2 times per week1250 (64.3)
  3 times per week286 (14.7)
  4 times per week192 (9.9)
  ≥5 times per week193 (9.9)
  Unknown23 (1.2)
Exercise intensity, n (%)
  Low0 (0.0)
  Low–moderate167 (8.6)
  Moderate510 (26.2)
  Moderate–vigorous985 (50.7)
  Vigorous91 (4.7)
  Unknown191 (9.8)
Exercise type, n (%)
  AE437 (22.5)
  RE385 (19.8)
  AE+RE957 (49.2)
  RE+impact training165 (8.5)
Exercise session duration (min), n (%)
  ≤30544 (28.0)
  >30–601148 (59.1)
  >60186 (9.6)
  Unknown66 (3.4)
  • *Proportion of survivors without SCT (n=3326).

  • †Proportion of survivors with SCT (n=189).

  • ‡Proportion of survivors from intervention groups (n=1944).

  • §Intervention duration of individual patients unknown for three studies, but mean or median was reported.

  • AE, aerobic exercise; BMI, body mass index; n, number; RE, resistance exercise; SCT, stem cell transplantation.